Welcome on Biogroup corporate website
We are pleased to welcome you on our corporate Website dedicated to investors.
Biogroup was founded back in 1998 by Stéphane Eimer in Alsace (East of France). Since then, we have been growing significantly both organically and through selective acquisitions. Biogroup is now the undisputed leader on the Medical lab testing market.
The Group has reached in 2020 a new step in its history by expanding abroad, with the acquisition of CMA Medina in Belgium. In 2021, we have further expanded our operations and acquired subsidiaries in Spain with Cerba Internacional and Analiza.
Our European expansion has reinforced our commitment to our core corporate values. We are a Group founded by biologists and managed and led by biologists. We value entrepreneurial spirit and regional footprint and remain the closest possible to our patients. Our biologists are committed to deliver high quality standards for the benefit of both our medical community and our patients.
Our commitment to deliver the best-in-class testing infrastructure during the Covid-19 health crisis has established Biogroup at the heart of the public health system.
We are committed to continuing the development of the group, investing in the innovations of tomorrow to offer the best healthcare service to our patients while maintaining our economic efficiency for the benefit of our investors and associated biologists.
Event
Friday, December 5th, 2025
Biogroup will present its Q3 2025 – financial statements.
The conference call will take place on Friday, December 5th, 2025 (date and time to be confirmed).
Invite will be sent by email.
News
— September 8th, 2025
IGAS (French General Inspectorate for Social Affairs) published in mid-July 2025 a report titled “Pertinence et efficience des dépenses de biologie médicale”, outlining recommendations for the French medical biology sector in the coming years.
These are recommendations only, addressed to the Health and Finance Ministries. They are not binding decisions and if several of these recommendations could be followed by the French Authorities, this would require additional steps, including going through the legislative process, before any implementation.
Accordingly, to avoid any premature speculations, Biogroup will not comment on this document at this stage.
Nevertheless, in this context we would like to reiterate that Biogroup launched a transformation plan at the end of 2023 to harmonize its operating model and to strengthen profitability, already achieving 50% of this plan by the end of 2025.
Reflecting these robust results, two rating agencies (S&P and Fitch) upgraded Biogroup in mid-July 2025 (B/B3/B).